Trial Profile
A double-blind, multicentre, prospective, randomised, placebo-controlled, concentration-escalating study of anti-CHST15 dsRNA in patients with Crohn's disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Dec 2015
Price :
$35
*
At a glance
- Drugs STNM 01 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- 21 Dec 2015 New trial record